A bibliometric and visual analysis of the use of ustekinumab in Crohn’s disease using CiteSpace

作者：Yi Chen, Jiaqi Zhang, Junling Wu, Hanwen Zhang, Hanwen Zhang, Zhe Luan, Zhizhuang Joe Zhao, Congyong Li, Yi-Ming Zhao, Hu Zhang, Hu Zhang, Shufang Wang, Gang Sun · 发表于：Frontiers in Pharmacology · 年份：2024 · DOI：10.3389/fphar.2023.1322319 · 被引用次数：10 · 研究领域：Inflammatory Bowel Disease、Autoimmune and Inflammatory Disorders Research、Microscopic Colitis

Background: The novel biologic agent ustekinumab (UST), a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, has been applied in the treatment of Crohn’s disease (CD). With the development of relevant research, the clinical treatment and favorable prognosis of UST in CD have garnered considerable attention. However, there is a lack of reports that present the current status of UST-related studies in a comprehensive and objective manner. Consequently, this study aims to visually analyze the current status and clinical trends of UST-related research, identify leading researchers, and recognize deficiencies using bibliometrics and knowledge mapping, which might assist in understanding future research priorities in that specific field. Methods: Published articles containing the use of UST in CD were retrieved from the Web of Science core collection database between 2008 and 2022. Then, the bibliometric analysis was performed, and a knowledge map was generated and visualized using the CiteSpace software. Results: A total of 479 articles published between 2008 and 2022 were included in the bibliometric analysis. These publications were authored by 185 scholars from 51 countries or regions, among which the United States (38.3%), Canada (16.9%) and England (10.0%) were predominant in publishing. The keyword analysis indicated that UST has long been a popular biologic agent, and its clinical efficacy, safety, and indication for vulnerable populations in ...